Trial Profile
A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary) ; Ipratropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors Mylan Pharmaceuticals Inc.
- 29 Oct 2020 Results of pooled analysis of data pooled from three phase II and two phase III studies (NCT03064113, NCT01704404, NCT02040792, NCT02459080, and NCT02512510) assessing the pharmacokinetics of Revefenacin and its major metabolite, published in the Clinical Pharmacokinetics
- 22 May 2013 Pharmacokinetic results presented at the 109th International Conference of the American Thoracic Society.
- 05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.